StockNews.com Begins Coverage on Actinium Pharmaceuticals (NYSE:ATNM)

StockNews.com initiated coverage on shares of Actinium Pharmaceuticals (NYSE:ATNM – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the stock.

Actinium Pharmaceuticals Stock Performance

NYSE:ATNM opened at $8.68 on Thursday. Actinium Pharmaceuticals has a 1-year low of $4.67 and a 1-year high of $15.12. The firm has a market capitalization of $223.34 million, a P/E ratio of -5.56 and a beta of 0.38.

About Actinium Pharmaceuticals

(Get Rating)

Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.